ArticleHuman vaccines & immunotherapeutics2025
Parental acceptance of HPV vaccinations at ages 9-10 in the United States.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mothers' intentions for adolescent sons' human papillomavirus vaccination in Japan: Psychosocial factors and relative influences across intention groups.Human vaccines & immunotherapeutics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the US, HPV vaccination is routinely recommended for 11-12-y-olds. This study explored parental attitudes toward initiation of the HPV vaccine at 9-10 y of age. Parents of 9-12-y-old children in the U.S. were invited to participate in a cross-sectional, online survey. The survey collected sociodemographic characteristics, awareness, knowledge, vaccination experiences, concerns, and opinions on HPV vaccination at ages 9-10. Among 250 parents, most supported vaccination at age 10 or younger (72% for boys, 77% for girls). Among parents whose children were vaccinated at 11-12-y-old, 90% said they would probably or definitely have accepted vaccination if offered earlier. Parents identified benefits to vaccination initiation at ages 9-10, including higher confidence in completion prior to sexual activity (reported by 60%), fewer injections at the 11-12-y-old visits (52%), and less concern about triggering sexual behavior (46%). Concerns about vaccination initiation at ages 9-10 included the inconvenience of separating from other vaccinations at 11-12-y-old visits (40%), difficulty engaging children in decision-making (39%), and lack of comfort discussing HPV vaccination topics including sexuality at this age (36%). Our study found high parental acceptance of HPV vaccination for 9-10-y-olds among those who were offered, and based on positive responses from parents to whom it had not been offered at that age. Our findings can be used to guide communication and information provided to parents to increase acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.